Late-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER...
BioAgilytix, a global bioanalytical Contract Research Organization (CRO), announces the expansion of its Australian laboratories through the op...
82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer t...
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction,...
Strategic collaboration pairs HCB101 (macrophage CD47-SIRPα blockade) with Aston Sci's Phase 2 HER2-directed DNA vaccine (AST-301) to drive durable...
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerativ...
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansi...
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...
Aignostics announced the launch of HETA Clinical, a new family of pan-cancer AI products spanning the pathology workflow from intake and evaluation to mole...
Systech, a global leader in pharmaceutical serialization and traceability solutions, has launched the ST33 Carton Serialization Station and ST34 Carton Ser...
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing...
Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, announced tha...
Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, announced...
Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed i...
© 2026 Biopharma Boardroom. All Rights Reserved.
